What initial systemic therapy would you offer a patient with metastatic colon cancer with BRAF V600E mutation, MSS, who is not an oxaliplatin candidate?

Would you include single-agent fluoropyrimidine, proceed with EC alone (like BEACON/the EC arm of BREAKWATER), or offer FOLFIRI despite the encorafenib-irinotecan drug-drug interaction?

Answer from: Medical Oncologist at Community Practice

In patients with BRAF-V600E mutant colon cancer who are not candidates for oxaliplatin, replacing the chemo backbone with FOLFIRI is what I’ve done for a few patients without any clinical or insurance issues.This is based on the BREAKWATER study, which, of note, had a FOLFIRI/EC arm - results ...

Comments

Medical Oncologist at Los Angeles VA Medical Center
That's quite helpful, Dr. @Pashtoon M. Kasi. Thank...

Medical Oncologist at City of Hope Orange County
I think it was probably just a practical and a sta...

Please select the option that best describes you:

What initial systemic therapy would you offer a patient with metastatic colon cancer with BRAF V600E mutation, MSS, who is not an oxaliplatin candidate?

Related Questions